Shares of Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report) rose 1% during trading on Tuesday . The company traded as high as $0.41 and last traded at $0.41. Approximately 100 shares traded hands during trading, a decline of 88% from the average daily volume of 857 shares. The stock had previously closed at $0.41.
Defence Therapeutics Stock Performance
The business’s 50-day simple moving average is $0.41 and its 200 day simple moving average is $0.55.
About Defence Therapeutics
Defence Therapeutics Inc engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments.
Read More
- Five stocks we like better than Defence Therapeutics
- Bank Stocks – Best Bank Stocks to Invest In
- NVIDIA’s Blackwell Chips Set for Arizona Manufacturing by TSMC?
- With Risk Tolerance, One Size Does Not Fit All
- Okta: Bullish Signals Suggest a Market Reversal Is Underway
- Business Services Stocks Investing
- BlackRock Makes Waves With $12B Private Credit Acquisition
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
